Overview

Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This is a study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with carotid stenosis scheduled for elective carotid endarterectomy
Phase:
Phase 2
Details
Lead Sponsor:
Tallikut Pharmaceuticals, Inc.
Treatments:
Atreleuton
Hydroxyurea
Lipoxygenase Inhibitors